Winston Gandy, MD
Cardiovascular Disease · Alpharetta, GANPI 1760481477
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.6%), speaking fees and education — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Boehringer Ingelheim at 44.7% of the total. Reporting peaked in 2019 at $3,447 and has fallen 95.9% since, to $140 in 2025.
Across 159 payments — averaging $36.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$3K
- Novo Nordisk$932
- Novo Nordisk AS$527
- Pfizer$297
- Alnylam Pharmaceuticals Inc.$234
- Kowa Pharmaceuticals America, Inc.$111
- plus $1K from 26 others
Across 848 payments — averaging $951.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$679K
- Novartis$69K
- Pfizer$21K
- Eli Lilly$19K
- Ironwood Pharmaceuticals, Inc$15K
- GSK$4K
- plus $1K from 1 others
What the payments were for
- Speaking & faculty fees$2,38041%
- Food & beverage$3,24657%
- Education$1132%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 13 | $2,566 |
| Novo Nordisk | 46 | $932 |
| Novo Nordisk AS | 11 | $527 |
| Pfizer | 18 | $297 |
| Alnylam Pharmaceuticals Inc. | 10 | $234 |
| Kowa Pharmaceuticals America, Inc. | 9 | $111 |
| Merck | 6 | $106 |
| Biotronik Inc. | 1 | $83 |
| E.r. Squibb & Sons, L.L.C. | 4 | $70 |
| Heartflow, Inc. | 1 | $61 |
| Johnson & Johnson | 3 | $58 |
| Amgen | 3 | $55 |
| Esperion Therapeutics, Inc. | 3 | $49 |
| AbbVie(2 entities) | 2 | $48 |
| Cvrx, Inc. | 2 | $47 |
| Baxter Healthcare | 2 | $44 |
| Edwards Lifesciences | 2 | $43 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $41 |
| AstraZeneca | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $36 |
| Abiomed | 2 | $34 |
| Arbor Pharmaceuticals, Inc. | 2 | $33 |
| Vital Connect, Inc | 2 | $33 |
| Medicure Pharma Inc. | 1 | $30 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 2 | $27 |
| Abbott | 1 | $25 |
| Eisai Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Medtronic | 1 | $12 |
| Bardy Diagnostics, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$2,350
How this compares
$5,739 in reported general payments places this provider in the 75th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 102 | $136,093 |
| OzempicSemaglutide | 25 | $40,786 |
| LivaloPitavastatin Calcium | 17 | $16,170 |
| Rosuvastatin Calcium | 120 | $1,540 |
| Levothyroxine Sodium | 98 | $1,354 |
| Amiodarone Hcl | 11 | $1,259 |
| Celecoxib | 30 | $1,227 |
| Nitroglycerin | 29 | $1,220 |
| Nitroglycerin PatchNitroglycerin | 24 | $914 |
| ClopidogrelClopidogrel Bisulfate | 71 | $874 |
| Prasugrel Hcl | 11 | $820 |
| Propafenone Hcl ErPropafenone Hcl | 11 | $779 |
| Potassium Chloride | 24 | $726 |
| Atorvastatin Calcium | 119 | $702 |
| Nifedipine ErNifedipine | 24 | $600 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $297 | $136,093102 claims |
| Novo NordiskOzempic | $932 | $40,78625 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $111 | $16,17017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Alpharetta
- Jason ReingoldAlpharetta$36K
- Narendra SinghJohns Creek$1.6M
- Hunter ChampionColumbus$1.5M
- Nicolas ChronosEatonton$912K
- Jaime BurkleGainesville$628K
- Joseph MillerAtlanta$573K
- Kashyap ChoksiThomasville$263K
- Utpal PandyaAtlanta$221K
- Randolph MartinAtlanta$177K
- Hiren ShahColumbus$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.